Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Blumenschein · SciRah

Researcher profile · Semantic Scholar

G. Blumenschein

Share profile

G. Blumenschein — researcher profile on SciRah

h-index: 83
Works: 581
Citations: 41K

Most-cited papers

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
D. Waterhouse, E. Garon, J. Chandler, M. McCleod +19 more
2020Journal of Clinical Oncology205 citations Open access
Semantic Scholar
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
F. Skoulidis, Haniel A. Araujo, Minh Truong Do, Yu Qian +127 more
2024Nature197 citations Open access
Semantic Scholar
Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer
L. Horn, J. Whisenant, H. Wakelee, K. Reckamp +19 more
2019Journal of Thoracic Oncology167 citations Open access
Semantic Scholar
Stereotactic Ablative Radiotherapy With or Without Immunotherapy for Early-Stage or Isolated Lung Parenchymal Recurrent Node-Negative Non-Small Cell Lung Cancer: An Open-Label, Randomized, Phase 2 Trial
Joe Y. Chang, S. Lin, W. Dong, Z. Liao +24 more
2023The Lancet161 citations Open access
Semantic Scholar
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
J. Luke, M. Patel, G. Blumenschein, E. Hamilton +26 more
2023Nature Medicine137 citations Open access
Semantic Scholar
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
M. Negrao, H. Araújo, G. Lamberti, Alissa J Cooper +62 more
2023Cancer Discovery136 citations Open access
Semantic Scholar
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
R. Hassan, G. Blumenschein, K. Moore, A. Santin +12 more
2020Journal of Clinical Oncology136 citations Open access
Semantic Scholar
Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.
L. Hong, M. Negrao, S. Dibaj, Run-Zhe Chen +33 more
2020Journal of Thoracic Oncology132 citations Open access
Semantic Scholar
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Jacob M. Sands, Myung-Ju Ahn, A. Lisberg, B. Cho +19 more
2025Journal of Clinical Oncology127 citations Open access
Semantic Scholar
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T. Kim, Yan-Shuo Chu, Mercy Misoi, M. Suarez-Almazor +34 more
2022Nature Communications108 citations Open access
Semantic Scholar
Poziotinib for EGFR exon 20 mutant NSCLC: clinical efficacy, resistance mechanisms and impact of insertion location on drug sensitivity
Y. Elamin, J. Robichaux, B. Carter, M. Altan +23 more
2022Cancer Cell96 citations Open access
Semantic Scholar
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial
Roshal R. Patel, K. He, H. Barsoumian, Joe Y. Chang +29 more
2021Radiotherapy and Oncology84 citations
Semantic Scholar
Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
Y. Elamin, J. Robichaux, B. Carter, M. Altan +12 more
2021Journal of Clinical Oncology72 citations Open access
Semantic Scholar
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC.
Myung-Ju Ahn, A. Lisberg, Yasushi Goto, Jacob Sands +22 more
2025Journal of Thoracic Oncology65 citations Open access
Semantic Scholar
Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
Wang Jing, Ting Xu, Li-Rong Wu, P. B. López +10 more
2022JTO Clinical and Research Reports55 citations Open access
Semantic Scholar
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
X. Le, Jyoti D. Patel, E. Shum, C. Baik +26 more
2024Journal of Clinical Oncology54 citations Open access
Semantic Scholar
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
J. Luke, M. Patel, E. Hamilton, B. Chmielowski +14 more
2020Journal of Clinical Oncology51 citations
Semantic Scholar
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer
G. Blumenschein, S. Devarakonda, M. Johnson, V. Moreno +23 more
2022Journal for ImmunoTherapy of Cancer48 citations Open access
Semantic Scholar
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
A. Hegde, Alexander Y. Andreev-Drakhlin, J. Roszik, Le Huang +18 more
2020ESMO Open48 citations Open access
Semantic Scholar
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
M. Gillison, G. Blumenschein, J. Fayette, J. Guigay +16 more
2022The Oncologist47 citations Open access
Semantic Scholar
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
R. Ramanathan, D. V. Von Hoff, F. Eskens, G. Blumenschein +7 more
2020Targeted oncology45 citations Open access
Semantic Scholar
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
J. McQuade, H. Hammers, H. Furberg, A. Engert +11 more
2022JAMA Oncology41 citations Open access
Semantic Scholar
Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma
R. Ferrarotto, L. Sousa, Lei Feng, F. Mott +16 more
2023Journal of Clinical Oncology40 citations Open access
Semantic Scholar
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC
S. Lin, Yan-Zong Lin, L. Yao, N. Kalhor +20 more
202039 citations
Semantic Scholar
Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors.
R. Gutierrez, P. Shah, O. Hamid, A. Garfall +12 more
202133 citations
Semantic Scholar
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
M. Negrao, A. G. Paula, D. Molkentine, Laura D Hover +18 more
2025Clinical Cancer Research28 citations Open access
Semantic Scholar
OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study
B. Sepesi, T. Cascone, W. William, H. Lin +28 more
2019Journal of Thoracic Oncology28 citations Open access
Semantic Scholar
Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05.
A. Lisberg, Myung-Ju Ahn, Satoru Kitazono, B. C. Cho +16 more
2024Journal of Clinical Oncology27 citations Open access
Semantic Scholar
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
M. Altan, Yan Wang, Juhee Song, J. Welsh +23 more
2023Journal for ImmunoTherapy of Cancer27 citations Open access
Semantic Scholar
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients
Tian-Jiao Wang, J. Navenot, Stavros Rafail, Cynthia Kurtis +29 more
2024Molecular Therapy: Methods & Clinical Development21 citations Open access
Semantic Scholar
Effect of Dexamethasone for Dyspnea in Patients with Cancer: A Parallel-Group, Multi-Site, Double-Blind, Randomized Clinical Trial
D. Hui, Veronica Puac, Z. Shelal, R. Dev +14 more
2022The Lancet Oncology19 citations Open access
Semantic Scholar
Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling
H. Tran, V. Lam, Y. Elamin, L. Hong +16 more
2021JCO Precision Oncology16 citations Open access
Semantic Scholar
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
M. Patel, J. Luke, E. Hamilton, B. Chmielowski +14 more
2020Journal for ImmunoTherapy of Cancer13 citations Open access
Semantic Scholar
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non–small cell lung cancer
Liza C. Villaruz, G. Blumenschein, G. Otterson, T. Leal
2023Cancer12 citations Open access
Semantic Scholar
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
N. Zhou, C. Leung, W. N. William, A. Weissferdt +33 more
2024Journal for ImmunoTherapy of Cancer11 citations
Semantic Scholar
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
R. Ferrarotto, L. Sousa, Yun Qing, D. Kaya +15 more
2021Advances in Therapy11 citations
Semantic Scholar
BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC.
Y. Elamin, S. Gandhi, M. Antonoff, F. Mott +11 more
2020Journal of Clinical Oncology11 citations
Semantic Scholar
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer
M. Altan, Janet Tu, D. Milton, Bulent Yilmaz +9 more
2023Cancer9 citations
Semantic Scholar
Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer
S. Lin, Heather Y. Lin, V. Verma, M. Xu-Welliver +16 more
2022Cancer Treatment and Research Communications9 citations Open access
Semantic Scholar
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials.
A. Tam, V. Papadimitrakopoulou, I. Wistuba, J. Lee +10 more
2020Clinical Radiology9 citations Open access
Semantic Scholar
Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers.
B. Nelson, Clark R. Andersen, Ying Yuan, D. Hong +16 more
2022Journal of Clinical Oncology8 citations
Semantic Scholar
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
Simon Heeke, Saumil Gandhi, Hai T. Tran, Vincent K. Lam +18 more
2025JTO Clinical and Research Reports7 citations Open access
Semantic Scholar
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
J. Reuss, S. Gandhi, D. Spigel, P. Janne +14 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
C. Molife, A. Brnabic, V. Stefaniak, M. Belger +4 more
2023Immunotherapy7 citations
Semantic Scholar
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
Kai-Wen Wang, Robyn Du, S. Roy-Chowdhuri, Zi-Ping Li +21 more
2023JTO Clinical and Research Reports7 citations Open access
Semantic Scholar
Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC).
Y. Elamin, M. Negrao, F. Fossella, L. Byers +11 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
801 PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients
E. Hamilton, S. Nikiforow, P. Bardwell, C. McInnis +18 more
20207 citations Open access
Semantic Scholar
A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).
G. Blumenschein, D. Davar, R. Gutierrez, N. Segal +3 more
20206 citations
Semantic Scholar
MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.
Melissa L. Johnson, T. Burns, J. Thompson, A. Spira +12 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
F. Skoulidis, Haniel A. Araujo, Minh Truong Do, Yu Qian +127 more
2025Nature4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Y. Elamin×17
Invite
Y. Elamin — researcher profile on SciRah
J. Heymach×16
Invite
J. Heymach — researcher profile on SciRah
M. Altan×15
Invite
M. Altan — researcher profile on SciRah
F. Fossella×14
Invite
F. Fossella — researcher profile on SciRah

×12

Invite

M. Negrao — researcher profile on SciRah

Invite

A. Tsao — researcher profile on SciRah

F. Skoulidis×11

Invite

F. Skoulidis — researcher profile on SciRah

Invite

T. Cascone — researcher profile on SciRah

Jian-Jun Zhang×9

Invite

Jian-Jun Zhang — researcher profile on SciRah

Invite

D. Gibbons — researcher profile on SciRah

Invite

J. Heymach — researcher profile on SciRah

Invite

X. Le — researcher profile on SciRah